Cardiovascular disease is one of the most significant public health issues in the world. Our commitment to cardiovascular disease remains steadfast, and supporting cross-sector collaborative programs and patient-advocacy initiatives is part of this commitment. A key focus of this work is moving from a reactive healthcare model toward a proactive and innovative public health approach aimed to predict and prevent the impact of serious diseases from occurring. Together, we are employing and testing not just one approach but a range of innovative initiatives to help improve patient outcomes and address population health.
Amgen has partnered with American Heart Association on Check. Change. Control. Cholesterol™ program, which aims to reduce the number of Americans who have heart attacks and strokes by improving cholesterol management of high-risk cardiovascular disease patients through a multifaceted approach.
See the ProgramAmgen has partnered with American College of Cardiology (ACC) on TRANSFORM: ACS, a program that aims to initiate lipid-lowering treatment closer to hospital discharge for ACS patients.
View Press ReleaseAmgen is part of the CDC Foundation’s Alliance for the Million Hearts campaign, an initiative focused on changing the way people think about and embrace CVD prevention — promoting simple and sustained steps that people can take to help protect their heart health.
Read the ArticleThis video provides a brief explanation of the basic tenets of extrapolation as it pertains to biosimilars. (0:50)
This video provides a high-level overview of what a biological drug is and how it differs from a small molecule drug. (0:47)
This video provides a high-level overview of biosimilars. The main goal of biosimilars is to create a drug that is similar to a reference product. (0:42)
See how Otezla may work in psoriatic arthritis. The specific mechanism(s) by which apremilast exerts its therapeutic action is not well defined. (3:30)
Learn about the PALACE 4 clinical trial data in DMARD-naïve patients. (11:52)
Learn about the RELIEF clinical trial data. (11:14)
Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab. Introducing VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.
Overview of the mechanism of LDL-C regulation and the role of PCSK9.
Speakers: Dominick J. Angiolillo, MD, PhD, FACC | Carl (Chip) Lavie, Jr, MD, FACC
Watch how LDL-C levels recommended by multiple cholesterol guidelines have decreased over time and understand current recommendations for very high-risk patients.
Learn how we can better manage cholesterol in high-risk patients and help reduce the risk of subsequent CV events.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Sripal Bangalore, MD, MHA
Learn about the MOA for EVENITY® (romosozumab-aqqg) in treatment of post-menopausal women who are at high risk of fracture.
Learn more about the Prolia® MOA for treatment of post-menopausal osteoporosis.
Watch Dr. Amar Majjhoo discuss the results of the SEAM-RA clinical trial on ENBREL as a monotherapy for maintaining remission in patients with RA. (29:06)
Watch Dr. Lawrence Leventhal discuss the results of the SEAM-PsA clinical trial on ENBREL as a monotherapy for treating patients with PsA. (19:36)
The Embark App provides patients with financial support information, medication reminders, injection site tracking & more—all in the palm of their hand. (4:05)
Watch a video about ENBREL Nurse Partners™ and how they can help your patient prepare for their first injection at home with supplemental support. (2:44)
Watch a video about ENBREL Support® services that provides helpful information for your patients on prescribed ENBREL therapy. (2:22)